Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DP-303c by CSPC Pharmaceutical Group for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Human Epidermal Growth Factor Receptor...
DP-303c by CSPC Pharmaceutical Group for Epithelial Ovarian Cancer: Likelihood of Approval
DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Epithelial Ovarian Cancer. According to...
DP-303c by CSPC Pharmaceutical Group for Peritoneal Cancer: Likelihood of Approval
DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Peritoneal Cancer. According to GlobalData,...
DP-303c by CSPC Pharmaceutical Group for Fallopian Tube Cancer: Likelihood of Approval
DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase II for Fallopian Tube Cancer. According to...
DP-303c by CSPC Pharmaceutical Group for Metastatic Breast Cancer: Likelihood of Approval
DP-303c is under clinical development by CSPC Pharmaceutical Group and currently in Phase III for Metastatic Breast Cancer. According to...